Dishman Carbogen Amcis Limited has released its investor presentation for the third quarter ended December 31, 2025. The company reported a Net Revenue of ₹7,198 million for Q3FY26, marking a 5.5% year-on-year increase from ₹6,823 million in Q3FY25. This growth was primarily driven by higher revenue from the CDMO segment, which saw a 6.7% increase to ₹6,297 million compared to the previous year. The Marketable Molecules (MM) segment revenue for Q3FY26 decreased by 2.4% to ₹901 million from ₹922 million in Q3FY25, mainly due to lower Quats revenue. However, for the nine months ended FY26 (9MFY26), Net Revenue stood at ₹20,805 million, a 4.3% increase from ₹19,952 million in 9MFY25, largely due to higher Cholesterol and Vitamin D analogues revenue contribution. EBITDA for Q3FY26 was ₹1,131 million, with an EBITDA margin of 15.7%, a decrease from 20.5% in Q3FY25. This margin contraction was attributed to lower contributions from late Phase III molecules in the CDMO segment and a higher composition of cholesterol revenue in the MM segment. Conversely, for 9MFY26, EBITDA increased to ₹4,027 million with a margin of 19.4%, up from ₹3,163 million and 15.9% in 9MFY25, driven by improved margins in both CDMO and MM segments. The company also noted that approximately ₹200 million (Rs. 20 crore) in supplies were deferred from Q3FY26 to Q4FY26 due to delayed intermediate supplies and holiday periods in Europe. Employee expenses included a one-time provision of approximately ₹33 million for severance pay and social insurance costs, and finance costs included a one-time expense of approximately ₹110 million for new syndication credit facilities.
